



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

expectation of 50% improvement at 12 weeks might not have been reasonable to assess the additional benefit of palliative radiotherapy. This limitation suggests that perhaps the initially planned endpoint was better suited to answer the study question, although it was unachievable because of difficulties with recruitment and patient deterioration.

The ROCS trial provides valuable data and alerts us that routine use of SEMS plus palliative radiotherapy is not indicated for patients with advanced oesophageal cancer, except for patients with high upper gastrointestinal bleeding risk. It also underscores the importance of patient selection in determining both which and how many modalities are offered to manage dysphagia associated with advanced oesophageal cancer.

We declare no competing interests.

*Lindsay L Puckett, Monica E Shukla
lpuckett@mcw.edu

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

- 1 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021; published online Feb 4. <https://doi.org/10.3322/caac.21660>.

- 2 Then EO, Lopez M, Saleem S, et al. Esophageal cancer: an updated Surveillance Epidemiology and End Results Database analysis. *World J Oncol* 2020; **11**: 55–64.
- 3 Lai A, Lipka S, Kumar A, et al. Role of esophageal metal stents placement and combination therapy in inoperable esophageal carcinoma: a systematic review and meta-analysis. *Dig Dis Sci* 2018; **63**: 1025–34.
- 4 Adamson D, Byrne A, Porter C, et al. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet Gastroenterol Hepatol* 2021; **6**: 292–303.
- 5 Javed A, Pal S, Dash NR, et al. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial. *J Gastrointest Cancer* 2012; **43**: 63–69.
- 6 Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. *Lancet* 2004; **364**: 1497–504.
- 7 Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. *Dis Esophagus* 2005; **18**: 131–39.
- 8 Martin EJ, Bruggeman AR, Nalawade VV, et al. Palliative radiotherapy versus esophageal stent placement in the management of patients with metastatic esophageal cancer. *J Natl Compr Canc Netw* 2020; **18**: 569–74.
- 9 Penniment MG, De Ieso PB, Harvey JA, et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). *Lancet Gastroenterol Hepatol* 2018; **3**: 114–24.
- 10 Conio M, Repici A, Battaglia G, et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. *Am J Gastroenterol* 2007; **102**: 2667–77.



Implications of COVID-19 for patients with pre-existing digestive diseases: an update

Published Online
February 1, 2021
[https://doi.org/10.1016/S2468-1253\(21\)00025-X](https://doi.org/10.1016/S2468-1253(21)00025-X)

The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and development of severe COVID-19 in patients with pre-existing digestive diseases has raised great concern since infection of the gastrointestinal tract was first reported in March, 2020.¹ In addition, patients with pre-existing digestive diseases are thought to be at increased risk of infection due to immune dysfunction.² In response, we published a Comment in *The Lancet Gastroenterology & Hepatology* on the implications of COVID-19 for such patients during the early stages of the pandemic.³ Our knowledge about COVID-19 has continued to expand, and we provide an updated overview of the implications of COVID-19 for patients with pre-existing digestive diseases.

Few studies assessing the risk of SARS-CoV-2 infection in patients with pre-existing digestive disease have included suitable control groups. A study using national

data from the US Department of Veterans Affairs health-care system included 88747 veterans tested for SARS-CoV-2 before May 15, 2020, and suggested that there was no difference in likelihood of testing positive for SARS-CoV-2 between those with and without a diagnosis of cirrhosis after adjustment for sociodemographic characteristics, comorbidities, and presenting symptoms.⁴ Two international registries—COVID-Hep and SECURE-Cirrhosis—were created to collate data from COVID-19 cases in patients with chronic liver diseases and liver transplant recipients. An analysis of 745 patients with chronic liver diseases with SARS-CoV-2 infection showed that baseline liver disease stage and alcohol-related liver disease were independent risk factors for death from COVID-19.⁵

There is no definitive evidence regarding infection risk in solid organ transplant recipients compared with patients without a transplant. A nationwide population

study in Italy found that the cumulative incidence of SARS-CoV-2 infection was higher in transplant recipients than in patients who had not had a transplant.⁶ When stratified by type of organ transplant, the cumulative incidence was higher for heart transplants and lower for liver transplants versus kidney transplants.⁶ However, more organ transplant recipients had two or three comorbidities than did the control population.⁶ An analysis of 151 liver transplant recipients with SARS-CoV-2 infection in the COVID-Hep and SECURE-Cirrhosis registries showed that liver transplantation was not independently associated with death, whereas known risk factors, such as increased age and presence of comorbidities were.⁷ For liver transplant recipients, most societies, such as the American Association for the Study of Liver Diseases and European Association for the Study of the Liver, advise against reducing immunosuppressive therapy to prevent SARS-CoV-2 infection. Reduction should only be considered under special circumstances (eg, medication-induced lymphopenia, or bacterial or fungal superinfection in case of severe COVID-19) after consultation with specialists.^{8,9}

Data linking pre-existing non-alcoholic fatty liver disease (NAFLD) with SARS-CoV-2 infection are scarce. A retrospective analysis of a large electronic health record database including 61.4 million adults showed that the cumulative incidence of COVID-19 was higher in patients with a primary diagnosis of metabolic syndrome (0.10% vs 0.01%, odds ratio [OR] 7.00 [95% CI 6.11–8.01]) than in patients without metabolic syndrome. The adjusted OR (aOR) of having COVID-19 was higher in patients if they were diagnosed with non-alcoholic steatohepatitis (aOR 4.93 [95% CI 4.06–6.00]) than if they were not.¹⁰ Moreover, NAFLD was independently associated with COVID-19 progression.¹¹

Whether patients with inflammatory bowel disease (IBD) are more susceptible to SARS-CoV-2 infection was a crucial question at the beginning of the pandemic. Several large cohort studies have provided epidemiological evidence that patients with IBD, including those receiving biologics or immunosuppressive medications, do not seem to have an increased risk of SARS-CoV-2 infection compared with the general population. For instance, a population-based cohort in the Netherlands showed that the incidence of COVID-19 in patients with IBD was similar to that of the general population.¹²

An early report from the SECURE-IBD registry showed that corticosteroids and aminosaliclates were associated with an increased risk of severe COVID-19, whereas TNF antagonists were not.¹³ An update in June, 2020, showed that combination therapy and thiopurines might be associated with an increased risk of severe COVID-19 compared with TNF antagonists.¹⁴ Similarly, even when corrected for age, patients who used aminosaliclates had an increased risk of severe COVID-19 compared with patients who did not use aminosaliclates (many of whom used TNF antagonists). Thus, it is still unclear whether immunomodulator or aminosaliclates use truly confers increased risk of severe COVID-19, or whether TNF antagonists reduce the risk of severe COVID-19. Notably, no significant differences were observed when comparing classes of biologics.¹⁴ Overall, the implications of these findings are still debated, due to study design and selection bias in such observational registries.

Given the potential risk of discontinuing IBD medications, such as disease flare and other complications, expert gastroenterology societies recommend continuation of medications except corticosteroids. Patients receiving a combination of two immunosuppressive drugs, such as thiopurine and a TNF antagonist, should discuss with their doctor if the combination therapy could be de-escalated.

Due to an unprecedented international effort, safe and effective vaccines against SARS-CoV-2 are being administered worldwide. Although the mRNA vaccines have not been tested in immunosuppressed populations such as those with IBD or chronic liver diseases, they do not contain live or live-attenuated viruses and are therefore not considered to pose infective risk. Most experts currently advocate vaccinating immunocompromised populations with the mRNA vaccines, including patients with IBD receiving biologics and immunosuppressive agents, because the vaccines have been shown to be efficacious and safe in the general population and the risk of COVID-19 complications in immunocompromised populations exceeds the uncertainty on vaccine safety in these groups. Similarly, other SARS-CoV-2 vaccines—eg, replication-incompetent vector vaccines, inactivated vaccines, and recombinant vaccines—are also considered to be safe to administer to patients with IBD. Vaccine efficacy might be decreased in patients with

chronic liver disease, IBD, or after liver transplantation, but most vaccines are generally recommended for these patients. Physicians should counsel patients that there is a possibility of reduced vaccine efficacy when receiving systemic corticosteroids. Further studies are necessary to document the immunogenicity to mRNA vaccines in immunosuppressed populations.

Outstanding questions pertinent to patients with pre-existing digestive condition include the long-term effect of COVID-19 on the natural history of digestive diseases, degree of immunity and risk of SARS-CoV-2 reinfection, the safety of emerging vaccines, whether biologics and immunosuppressive drugs influence the effectiveness of the SARS-CoV-2 vaccine, and the duration of vaccine-induced immunity. These points will need to be addressed by the medical community in the near future.

FR is consultant to Agomab, Allergan, AbbVie, Boehringer-Ingelheim, Celgene/BMS, CDISC, Cowen, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Janssen, Koutif, Mestag, Metacrine, Morphic, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surrozen, Takeda, Techlab, Theravance, Thetis, and UCB, outside the submitted work. GGK has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, and Takeda; has received research support from Ferring, Janssen, AbbVie, GlaxoSmith Kline, Merck, and Shire; has been a consultant for Gilead; and shares ownership of a patent (treatment of inflammatory disorders, autoimmune disease, and PBC: UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. Sept 7, 2018), all outside the submitted work. SCN has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, Menarini, Tilotts, Ferring, and Takeda; and has received research support from Olympus, Ferring, Janssen, and AbbVie, outside the submitted work. All other authors declare no competing interests.

Ren Mao, Florian Rieder, Shomron Ben-Horin, Gilaad G Kaplan, Siew C Ng, Grace LH Wong, Subrata Ghosh, *Min-Hu Chen
chenminhu@mail.sysu.edu.cn

Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China (RM, M-HC); Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA (FR); Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA (FR); Department of Gastroenterology, Sheba Medical Center, Tel-HaShomer, Israel (SB-H); Sackler School of Medicine, Tel Aviv University,

Tel Aviv, Israel (SB-H); Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada (GGK); Department of Medicine and Therapeutics, Institute of Digestive Disease (SCN, GLHW) and State Key Laboratory of Digestive Diseases, LKS Institute of Health Science (SCN, GLHW), Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; National Institute for Health Research, Biomedical Research Institute, Institute of Translational Medicine, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (SG)

- Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterology* 2020; **158**: 1831–33.
- Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. *Lancet Gastroenterol Hepatol* 2020; **5**: 776–87.
- Mao R, Liang J, Shen J, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. *Lancet Gastroenterol Hepatol* 2020; **5**: 425–27.
- Ioannou GN, Liang PS, Locke E, et al. Cirrhosis and SARS-CoV-2 infection in US veterans: risk of infection, hospitalization, ventilation and mortality. *Hepatology* 2020; published online Nov 21. <https://doi.org/10.1002/hep.31649>.
- Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. *J Hepatol* 2020; published online Oct 6. <https://doi.org/10.1016/j.jhep.2020.09.024>.
- Trapani S, Masiero L, Puoti F, et al. Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: a nationwide population-based study. *Am J Transplant* 2020; published online Dec 5. <https://doi.org/10.1111/ajt.16428>.
- Webb GJ, Marjot T, Cook JA, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. *Lancet Gastroenterol Hepatol* 2020; **5**: 1008–16.
- Boettler T, Marjot T, Newsome PN, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-EASCP position paper after 6 months of the pandemic. *JHEP Rep* 2020; **2**: 100169.
- Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel consensus statement. *Hepatology* 2020; **72**: 287–304.
- Ghoneim S, Butt MU, Hamid O, Shah A, Asaad I. The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: a population-based study. *Metabol Open* 2020; **8**: 100057.
- Hashemi N, Viveiros K, Redd WD, et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience. *Liver Int* 2020; **40**: 2515–21.
- Derikx LAAP, Lantinga MA, de Jong DJ, et al. Clinical outcomes of COVID-19 in patients with inflammatory bowel disease: a nationwide cohort study. *J Crohns Colitis* 2020; published online Oct 20. <https://doi.org/10.1093/ecco-jcc/jjaa215>.
- Brenner EJ, Ungaro RC, Geary RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. *Gastroenterology* 2020; **159**: 481–91.
- Ungaro RC, Brenner EJ, Geary RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. *Gut* 2020; published online Oct 20. <https://doi.org/10.1136/gutjnl-2020-322539>.



Relevance of reproductive health to comprehensive hepatology care

In the USA, chronic liver disease is the sixth most common cause of mortality in young women aged 20–44 years.¹ Moreover, non-alcoholic fatty liver disease, which is now the leading cause of chronic liver disease in the USA, has seen the most marked rise in incidence in young adults compared with other age groups.² These

epidemiological trends are consistent with pregnancy data showing a near tripling of the prevalence of non-alcoholic fatty liver disease in pregnancy over the past decade, and an increase in alcohol-related liver disease in women of reproductive age.^{3,4} In light of this growing population, hepatology providers must now address